U.S. FDA approves Mirati's lung cancer drug

Published 12/12/2022, 05:39 PM
Updated 12/12/2022, 07:15 PM
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly
AMGN
-
MRTX
-

By Deena Beasley

(Reuters) -The U.S. Food and Drug Administration approved Mirati Therapeutics (NASDAQ:MRTX) Inc's lung cancer drug adagrasib, the company said on Monday, sending its shares up more than 8% in extended trading.

Mirati's drug has been approved for treating adult patients with advanced lung cancer as determined by an FDA-approved test, who have received at least one prior systemic therapy.

Adagrasib, an oral drug, is designed to target a mutated form of a gene known as KRAS that occurs in about 13% of non-small cell lung cancers (NSCLC), the most common form of the disease, and less frequently in some other solid tumors.

Mirati said the drug will be sold under the brand name Krazati at a price of $19,750 for a 200 milligram tablet/180 count bottle.

Another KRAS inhibitor, Amgen Inc (NASDAQ:AMGN)'s Lumakras, is already available to treat patients suffering from advanced lung cancer as a second-line therapy, after an initial therapy fails or stops working.

© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

Third-quarter sales of Lumakras, which was approved last year, totaled $75 million.

Mirati Chief Executive David Meek said in a recent interview that the drug is a compelling choice. "I think physicians and patients are going to appreciate having an effective option," he told Reuters, noting that 43% of second-line trial patients responded to adagrasib. Shares of Mirati have fallen about 55% since early this month, after the company's presentation of early data from studies of adagrasib in combination with Merck & Co's immunotherapy Keytruda as an initial treatment for metastatic NSCLC. The results showed that the combination helped about half of trial participants. But Mirati said it would first move to a trial only in patients with lower levels of the protein targeted by Keytruda, with a high bar of proving superiority over standard of care. Wall Street analysts, initially encouraged by the efficacy and safety findings, questioned Mirati's strategy for future combination studies. "We see a long and challenging path to Phase 3 data ... and possibility for an acquisition is likely off the table for now," BMO Capital Markets analyst Evan Seigerman said in a research note before the approval.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.